Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Your provider will monitor how youre doing and adjust things as needed
Sanyal AJ, Kaplan LM, Frias JP et al (2024) Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Sustainable weight loss is about metabolic health, not just the number on the scale
Implications for Chronic Kidney Disease and Global Health Lead author Professor Sunil Badve, Professorial Fellow at The George Institute for Global Health and UNSW Sydney said the study expanded current knowledge about this class of drugs in key areas, including benefits in people with CKD, and in people with and without diabetes
